Your browser doesn't support javascript.
loading
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
McKay, Rana R; Leucht, Katharina; Xie, Wanling; Jegede, Opeyemi; Braun, David A; Atkins, Michael B; Grimm, Marc-Oliver; Choueiri, Toni K.
Affiliation
  • McKay RR; Department of Medicine, University of California San Diego, La Jolla, CA, USA.
  • Leucht K; Department of Urology, University of California San Diego, La Jolla, CA, USA.
  • Xie W; Department of Urology, Universitaetsklinikum Jena, Jena, Germany.
  • Jegede O; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Braun DA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Atkins MB; Department of Medicine, Yale University, New Haven, CT, USA.
  • Grimm MO; Department of Medicine, Georgetown University, Washington, DC, USA.
  • Choueiri TK; Department of Urology, Universitaetsklinikum Jena, Jena, Germany.
Oncologist ; 29(4): 324-331, 2024 Apr 04.
Article in En | MEDLINE | ID: mdl-37950901
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Limits: Humans Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2024 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Limits: Humans Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2024 Type: Article Affiliation country: United States